Consistent delivery; growth momentum to sustain in H2



Information Technology >

Result Update

October 25, 2025

CMP (Rs): 1,760 | TP (Rs): 1,850

Coforge posted a strong operating performance in Q2. Revenue grew 4.5% QoQ to USD462.1mn (5.9% in CC), ahead of our estimate of 5% CC. Revenue growth was broad-based in Q2, led by TTH (6.4% QoQ in USD term), Others (5.9%; includes Healthcare, Retail, Hi-tech, Manufacturing), and BFSI (4.0%). Coforge signed 5 large deals with total order intake of USD514mn, lifting the next 12M executable orderbook to USD1.63bn, up ~27% YoY. Annualized revenue per billable employee in the IT business inched up 3%/17% QoQ/YoY to ~USD70k on the back of AI-led platforms adoption; the management expects the trend to continue. It remains confident about the revenue growth momentum enduring in FY26, with H2 being better than H1, supported by strong deal wins and healthy pipeline. It aspires to achieve EBITM of 14% in FY26 and to maintain the margin level as the minimum threshold going forward. In addition, it aims to maintain FCF/PAT in the 75-80% range, ahead. We tweak FY26-28E adjusted EPS by ~3%, factoring in the Q2 performance. We retain ADD on the stock while we revise up our TP by \sim 6% to Rs1,850 (from Rs1,750) at 32x Sep-27E EPS.

Results Summary

Revenue grew 4.5% QoQ (5.9% in CC) to USD462.1mn, better than our expectations of 5% in CC. Revenue growth was broad-based, driven by TTH (6.4% QoQ in USD terms), Others (5.9%), BFS (4.0%), Insurance (1.8%), and 'Government outside India' (0.4%). EBITM was up by 240bps sequentially to 14%, above our expectations of 13.5%. There is a convergence between GAAP and non-GAAP (exchange vs factsheet format reported) EBITM in Q2. Reported net profit grew 18.4% QoQ to Rs3.8bn, above our estimate of Rs3.4bn, on higher other income. Deal intake TCV stood at USD514mn vs USD507mn in Q1. Headcount grew 2.1% QoQ to 34,896. LTM attrition (ex-BPS) remained steady at 11.4% vs 11.3% QoQ. The company declared interim dividend of Rs4/sh. What we liked: Broad-based revenue growth momentum, healthy deal intake, EBITM beat, and convergence between GAAP and non-GAAP EBITM. What we did not like: Higher DSO.

Earnings Call KTAs

1) Despite the uncertain macro, demand remained resilient and continued to improve on the margin, supported by solid trends across banking, insurance, and travel. The company's continued focus on driving robust organic growth complements its successful integration of acquisitions. 2) Banking demand remains strong, supported by lower interest rates, regulatory shifts, and adoption of real-time transactions across payments and settlements. 3) Insurance is entering an above-trend growth phase (P&C: ~4.5%; Life and Annuities: ~5%), driven by complex risks, focus on specialized products like cyber, higher interest rates, and growing interest in savings products...(contd)...

Coforge: Financial Snapshot (Consolidated)								
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E			
Revenue	91,790	120,507	161,041	188,484	219,215			
EBITDA	14,277	16,937	28,314	33,921	39,290			
Adj. PAT	8,080	8,121	14,674	17,203	20,850			
Adj. EPS (Rs)	26.1	24.3	43.9	51.4	62.3			
EBITDA margin (%)	15.6	14.1	17.6	18.0	17.9			
EBITDA growth (%)	11.5	18.6	67.2	19.8	15.8			
Adj. EPS growth (%)	9.2	(7.1)	80.6	17.2	21.2			
RoE (%)	24.1	16.2	21.5	22.0	23.1			
RoIC (%)	29.8	17.7	21.1	23.6	27.0			
P/E (x)	67.3	72.5	40.9	34.2	28.2			
EV/EBITDA (x)	38.2	32.2	19.2	16.1	13.9			
P/B (x)	15.0	9.2	8.1	7.0	6.1			
FCFF yield (%)	1.2	1.2	2.0	3.4	4.1			

Source: Company, Emkay Research

Target Price – 12M	Sep-26
Change in TP (%)	5.7
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	5.1

Stock Data	COFORGE IN
52-week High (Rs)	2,005
52-week Low (Rs)	1,191
Shares outstanding (mn)	334.6
Market-cap (Rs bn)	589
Market-cap (USD mn)	6,703
Net-debt, FY26E (Rs mn)	(7,158.9)
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	3,385.9
ADTV-3M (USD mn)	38.5
Free float (%)	99.5
Nifty-50	25,795.2
INR/USD	87.9
Shareholding,Sep-25	
Promoters (%)	0.0
FPIs/MFs (%)	34.1/54.9

Price Performance							
(%)	1M	3M	12M				
Absolute	8.4	5.0	14.3				
Rel. to Nifty	5.3	2.0	8.1				

1-Year share price trend (Rs)



Dipeshkumar Mehta

dipeshkumar.mehta@emkayglobal.com +91-22-66121253

Jimit Gandhi

jimit.gandhi@emkayglobal.com +91-22-66121255

Shivang Bagla

shivang.bagla@emkayglobal.com +91-22-66242491

...(contd)...4) Healthcare has emerged as an expanding segment, driven by demand for AIbased automation and data-driven patient care platforms, with the company targeting a USD100mn business size by year-end. 5) The 'Government outside India' segment surpassed USD150mn and is expected to move towards USD200mn run-rate in coming quarters. 6) The Sabre account has reached a steady state, with no further ramp-up expected in Q3. 7) Of the five large deals closed in Q2, three originated in North America (two in insurance and one in travel; two of these were new client contracts). The remaining two deals came from APAC. 8) Discounting and mortgage income from long-term contracts have been reclassified under Other Income, with Q1 figures restated for consistency. Going forward, the management will emphasize reported EBIT, FCF/PAT conversion, and revenue as the primary performance indicators. 9) Coforge implemented wage hike, effective October, and expects its impact to be in line with past periods' (~100-150bps); this would be partly offset by lower ESOP costs and D&A. 10) ETR is expected to be 23.5-24%. 11) Hedge book increased due to business growth and incremental position for the Cigniti business (did not take a hedge position earlier). As a policy, the company hedges on rolling-four-quarter basis, with 90% of the net exposure for the immediate quarter followed by 80%, 70%, and 60% for subsequent quarters.

Update on AI/Gen AI

i) The management views AI as a tailwind, enabling enterprise-wide adoption and driving revenue per employee to ~USD70,000. ii) Coforge has embedded proprietary AI platforms, such as CodeInsightAI (for code reverse engineering), BlueSwan (for orchestration), Forge-X (for rapid transformation), and Quasar AI (multi-framework agents, secure RAG, LLM routing) into its service fabric, enabling clients to move from AI pilots to enterprise adoption. iii) The company developed a custom SLM (small language model) for low-code development, and positions AI as a tailwind for firms that combine domain expertise with AI capability. iv) Coforge is embedding AI early in client engagements and using platform-led deliveries to accelerate time-to-value, reduce time-to-production, and create recurring consumption through agent services.

Exhibit 1: Quarterly snapshot								
(Rs mn)	Q2FY26	Q1FY26	QoQ (%)	Q2FY25	YoY (%)			
Revenue (USD mn)	462.1	442.4	4.5	365.1	26.6			
Revenue	39,857	36,886	8.1	30,256	31.7			
Operating expenses	32,575	31,031		25,330				
EBITDA	7,282	5,855	24.4	4,926	47.8			
- Margin (%)	18.3	15.9	240	16.3	200			
Depreciation	1,719	1,592		1,140				
EBIT	5,563	4,263	30.5	3,786	46.9			
- Margin (%)	14.0	11.6	240	12.5	140			
Other income	19	-610		-455				
Pre-tax profit	5,582	3,653	52.8	3,331	67.6			
Tax provided	1,328	792		864				
Minority Interest	496	-312		447				
Profit after tax	3,758	3,173		2,020				
Emkay - Net profit	3,758	3,464	8.5	2,310	62.7			
EPS (Rs)	11.2	10.4	8.4	6.9	62.1			

Source: Company, Emkay Research

his report is intended for Team White Marque Solutions(team.emkay@whitemarquesolutior

Exhibit 2: Actuals vs estimates

(D)		Estim	ate	Varia	tion		
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comments	
Net revenue (USD mn)	462	465	467	-0.5%	-1.1%	Revenue growth in CC terms was better than estimated, although USD revenue missed estimates due to higher hedge losses and cross-currency headwinds.	
Sales	39,857	40,744	40,986	-2.2%	-2.8%		
EBIT	5,563	5,513	5,611	0.9%	-0.9%	EBITM was above estimates.	
EBIT margin	14.0%	13.5%	13.7%	40 bps	30 bps		
Adj PAT	3,758	3,432	3,608	9.5%	4.2%	Reported PAT beat expectations due to better operating performance and higher other income (largely forex gainled).	


Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates

(Rs mn)	FY26E		FY27E			FY28E			
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue (USD mn)	1,870	1,862	-0.4%	2,150	2,142	-0.4%	2,472	2,463	-0.4%
YoY growth	29.4%	28.9%		15.0%	15.0%		15.0%	15.0%	
Revenue	161,924	161,041	-0.5%	189,228	188,484	-0.4%	220,021	219,215	-0.4%
EBIT	21,681	21,484	-0.9%	25,583	26,090	2.0%	29,918	30,776	2.9%
EBIT margin (%)	13.4	13.3		13.5	13.8		13.6	14.0	
Net Profit	14,284	14,674	2.7%	16,676	17,203	3.2%	20,322	20,850	2.6%
EPS (Rs)	42.7	43.9	2.7%	49.9	51.4	3.1%	60.8	62.3	2.5%

Source: Company, Emkay Research

Exhibit 4: Coforge - One-year forward PER



Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team emkay@whitemarquesolution

Coforge: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	91,790	120,507	161,041	188,484	219,215
Revenue growth (%)	14.5	31.3	33.6	17.0	16.3
EBITDA	14,277	16,937	28,314	33,921	39,290
EBITDA growth (%)	11.5	18.6	67.2	19.8	15.8
Depreciation & Amortization	3,186	4,276	6,830	7,832	8,514
EBIT	11,091	12,661	21,484	26,090	30,776
EBIT growth (%)	8.5	14.2	69.7	21.4	18.0
Other operating income	-	-	-	-	-
Other income	614	1,647	809	837	1,512
Financial expense	1,256	1,347	1,795	1,672	1,455
PBT	10,449	12,961	20,498	25,255	30,833
Extraordinary items	0	0	(291)	0	0
Taxes	2,093	3,326	4,753	6,061	7,708
Minority interest	(276)	(1,514)	(1,071)	(1,991)	(2,275)
Income from JV/Associates	-	-	-	-	-
Reported PAT	8,080	8,121	14,383	17,203	20,850
PAT growth (%)	19.0	0.5	77.1	19.6	21.2
Adjusted PAT	8,080	8,121	14,674	17,203	20,850
Diluted EPS (Rs)	26.1	24.3	43.9	51.4	62.3
Diluted EPS growth (%)	9.2	(7.1)	80.6	17.2	21.2
DPS (Rs)	15.5	15.2	16.0	19.0	23.2
Dividend payout (%)	59.2	62.8	37.2	37.0	37.2
EBITDA margin (%)	15.6	14.1	17.6	18.0	17.9
EBIT margin (%)	12.1	10.5	13.3	13.8	14.0
Effective tax rate (%)	20.0	25.7	23.2	24.0	25.0
NOPLAT (pre-IndAS)	8,869	9,412	16,502	19,828	23,082
Shares outstanding (mn)	309	334	335	335	335

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	10,449	12,536	20,207	25,255	30,833
Others (non-cash items)	5,046	6,483	6,830	7,832	8,514
Taxes paid	(3,661)	(3,959)	(4,753)	(6,061)	(7,708)
Change in NWC	(2,800)	(2,689)	(2,293)	(3,664)	(4,316)
Operating cash flow	9,034	12,371	19,991	23,361	27,322
Capital expenditure	(2,598)	(5,572)	(9,259)	(5,090)	(5,110)
Acquisition of business	0	(20,810)	0	0	0
Interest & dividend income	120	714	0	0	0
Investing cash flow	(2,478)	(24,483)	(9,306)	(5,090)	(5,110)
Equity raised/(repaid)	7	22,015	-	0	0
Debt raised/(repaid)	(2,556)	2,139	(1,005)	(3,000)	(1,000)
Payment of lease liabilities	0	(866)	0	0	0
Interest paid	-	-	-	-	-
Dividend paid (incl tax)	(4,781)	(5,097)	(5,353)	(6,357)	(7,763)
Others	(1,540)	(1,438)	0	0	0
Financing cash flow	(8,870)	16,753	(6,358)	(9,357)	(8,763)
Net chg in Cash	(2,314)	4,641	4,327	8,914	13,450
OCF	9,034	12,371	19,991	23,361	27,322
Adj. OCF (w/o NWC chg.)	11,834	15,060	22,284	27,025	31,639
FCFF	6,436	6,799	10,732	18,271	22,212
FCFE	5,300	6,166	8,937	16,599	20,757
OCF/EBITDA (%)	63.3	73.0	70.6	68.9	69.5
FCFE/PAT (%)	65.6	75.9	62.1	96.5	99.6
FCFF/NOPLAT (%)	72.6	72.2	65.0	92.1	96.2

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	618	669	669	669	669
Reserves & Surplus	35,648	63,123	72,154	82,999	96,086
Net worth	36,266	63,792	72,823	83,668	96,755
Minority interests	1,003	19,498	20,569	22,560	24,835
Non-current liab. & prov.	(5,117)	(3,286)	(3,286)	(3,286)	(3,286)
Total debt	4,366	7,005	6,000	3,000	2,000
Total liabilities & equity	39,412	90,708	100,517	111,106	126,309
Net tangible fixed assets	4,760	7,837	11,879	10,802	9,554
Net intangible assets	4,395	11,296	10,578	8,667	6,587
Net ROU assets	2,637	3,399	3,935	4,182	4,106
Capital WIP	232	4,131	200	200	200
Goodwill	11,738	38,430	40,930	40,930	40,930
Investments [JV/Associates]	0	1,457	0	0	0
Cash & equivalents	3,352	8,832	13,159	22,072	35,522
Current assets (ex-cash)	28,380	44,055	55,215	64,613	75,138
Current Liab. & Prov.	16,082	28,729	35,379	40,361	45,727
NWC (ex-cash)	12,298	15,326	19,836	24,253	29,411
Total assets	39,412	90,708	100,517	111,106	126,309
Net debt	1,014	(1,827)	(7,159)	(19,072)	(33,522)
Capital employed	39,412	90,708	100,517	111,106	126,309
Invested capital	33,191	72,889	83,223	84,652	86,481
BVPS (Rs)	117.3	190.8	217.6	250.1	289.2
Net Debt/Equity (x)	-	-	(0.1)	(0.2)	(0.3)
Net Debt/EBITDA (x)	0.1	(0.1)	(0.3)	(0.6)	(0.9)
Interest coverage (x)	9.3	10.6	12.4	16.1	22.2
RoCE (%)	30.5	21.7	23.5	25.8	27.7

Source: Company, Emkay Research

Valuations and key Ratios							
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E		
P/E (x)	67.3	72.5	40.9	34.2	28.2		
EV/CE(x)	13.1	6.0	5.5	5.0	4.4		
P/B (x)	15.0	9.2	8.1	7.0	6.1		
EV/Sales (x)	5.9	4.5	3.4	2.9	2.5		
EV/EBITDA (x)	38.2	32.2	19.2	16.1	13.9		
EV/EBIT(x)	49.1	43.0	25.4	20.9	17.7		
EV/IC (x)	16.4	7.5	6.5	6.4	6.3		
FCFF yield (%)	1.2	1.2	2.0	3.4	4.1		
FCFE yield (%)	0.9	1.0	1.5	2.8	3.5		
Dividend yield (%)	0.9	0.9	0.9	1.1	1.3		
DuPont-RoE split							
Net profit margin (%)	8.8	6.7	9.1	9.1	9.5		
Total asset turnover (x)	2.7	1.9	1.8	1.9	1.9		
Assets/Equity (x)	1.0	1.2	1.3	1.3	1.3		
RoE (%)	24.1	16.2	21.5	22.0	23.1		
DuPont-RoIC							
NOPLAT margin (%)	9.7	7.8	10.2	10.5	10.5		
IC turnover (x)	3.1	2.3	2.1	2.2	2.6		
RoIC (%)	29.8	17.7	21.1	23.6	27.0		
Operating metrics							
Core NWC days	48.9	46.4	45.0	47.0	49.0		
Total NWC days	48.9	46.4	45.0	47.0	49.0		
Fixed asset turnover	3.0	2.3	2.0	2.2	2.4		
Opex-to-revenue (%)	84.3	85.9	82.4	82.0	82.1		

Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

Coforge (COFORGE IN)

India Equity Research | Result Update

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
01-Oct-25	1,601	1,750	Add	Dipeshkumar Mehta
16-Sep-25	1,780	1,850	Add	Dipeshkumar Mehta
25-Jul-25	1,689	1,850	Add	Dipeshkumar Mehta
01-Jul-25	1,923	1,960	Add	Dipeshkumar Mehta
06-May-25	1,485	1,640	Add	Dipeshkumar Mehta
31-Mar-25	1,622	1,640	Reduce	Dipeshkumar Mehta
24-Jan-25	1,847	1,720	Reduce	Dipeshkumar Mehta
01-Jan-25	1,926	1,720	Reduce	Dipeshkumar Mehta
29-Dec-24	1,890	1,350	Reduce	Dipeshkumar Mehta
23-Oct-24	1,512	1,350	Reduce	Dipeshkumar Mehta
01-Oct-24	1,425	1,280	Reduce	Dipeshkumar Mehta
23-Jul-24	1,236	1,240	Reduce	Dipeshkumar Mehta
01-Jul-24	1,104	1,100	Reduce	Dipeshkumar Mehta
09-Jun-24	1,086	1,040	Reduce	Dipeshkumar Mehta
03-Jun-24	1,003	1,040	Reduce	Dipeshkumar Mehta
27-May-24	1,053	1,040	Reduce	Dipeshkumar Mehta
03-May-24	897	1,040	Reduce	Dipeshkumar Mehta
31-Mar-24	1,100	1,210	Reduce	Dipeshkumar Mehta
01-Mar-24	1,301	1,260	Reduce	Dipeshkumar Mehta
23-Jan-24	1,240	1,260	Reduce	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team emkay@whitemarquesolution

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 25, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 25, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 25, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

Coforge (COFORGE IN)

India Equity Research | Result Update

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution